I'm relentless and thrive in very challenging business environments.The driving force in my professional journey are innovation and scale: in biotech or SaaS. I embrace challenge and relish overcoming obstacles. I'm a hands-on leader adept at articulating a strategic vision and executing it with precision. My sweet spot lies in companies ranging from 100 to 500 employees. I've worn multiple hats - from cofounder to CEO, COO, and CFO - fueled by an unwavering commitment to scalability.For all these ventures, I relied on strategic thinking, appropriate fundings and operational excellence.Strategic Thinking is my compass. It remains the backbone of a successful plan - even if I agree that strategy can be eaten by culture for breakfast - I will come back to culture later. It relies on a good SWOT, on market trends and... a clear understanding of the Total Addressable Market.With a proven track record in raising over €100m (incl. private fundings and one IPO), I orchestrated financing strategies to propel ventures forward, whether through organic growth or strategic acquisitions.To deliver the best possible outcomes, I'm obsessed with optimizing organizational efficiency and alignment. I have the ability to lead and motivate. I implement rigorous OKR frameworks, single source of truth to sync teams, drive performance and foster a culture of scaling and accountability. I was in charge of acquiring several tech and service companies to foster the growth of the companies I worked with or to bring additional tech capabilities. I conducted the assessment (Due Diligence), the financing of these acquisitions (cash or equity, upfront or earn-out) and their post-merger integration! This is a real stress-test of our supposed operational excellence.Last but not least, since I mentioned that culture can eat strategy for breakfast - and I'm a strong advocate of a healthy culture: trust, candor and challenge, commitment and accountability.At Splio, I led transformative initiatives, propelling the company from a €3m ARR to €30m profitable ARR within 6 years through a meticulous focus on operational excellence (incl. 4 acquisitions).At Domain Therapeutics, I raised funds and signed strategic partnerships w/ major pharma companies (US, Japan, Canada) and set up a business model with dedicated SPVs for each drug candidate.At Come&Stay, I led the IPO of the company, to x8 revenue in 4 years through organic growth and 3 international acquisitions (US, Denmark).I'm now open to engage with new ventures in tech (biotech / IT) as C-level or cofounder.